Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1995 1
1997 1
2001 1
2005 2
2007 1
2012 1
2013 1
2014 2
2015 2
2016 2
2017 3
2018 5
2020 5
2021 6
2022 3
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
Koch MW, Kaur S, Sage K, Kim J, Levesque-Roy M, Cerchiaro G, Yong VW, Cutter GR, Metz LM. Koch MW, et al. Ann Neurol. 2021 Dec;90(6):940-948. doi: 10.1002/ana.26239. Epub 2021 Oct 15. Ann Neurol. 2021. PMID: 34590328 Clinical Trial.
OBJECTIVE: Primary progressive multiple sclerosis (PPMS) does not respond well to immunomodulatory or immunosuppressive treatment. Chronic activation of microglia has been implicated in the pathophysiology of PPMS. The antimalarial drug hydroxychloroquine (HC …
OBJECTIVE: Primary progressive multiple sclerosis (PPMS) does not respond well to immunomodulatory or immunosuppressive treatm …
Microglia in multiple sclerosis - pathogenesis and imaging.
Airas L, Yong VW. Airas L, et al. Curr Opin Neurol. 2022 Jun 1;35(3):299-306. doi: 10.1097/WCO.0000000000001045. Curr Opin Neurol. 2022. PMID: 35674072 Review.
PURPOSE OF REVIEW: Microglia normally protects the central nervous system (CNS) against insults. However, their persistent activation in multiple sclerosis (MS) contributes to injury. Here, we review microglia activation in MS and their detection using positron emis …
PURPOSE OF REVIEW: Microglia normally protects the central nervous system (CNS) against insults. However, their persistent activation in …
Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis.
Brown D, Moezzi D, Dong Y, Koch M, Yong VW. Brown D, et al. Neurotherapeutics. 2021 Jan;18(1):387-400. doi: 10.1007/s13311-020-01002-5. Epub 2021 Jan 6. Neurotherapeutics. 2021. PMID: 33410109 Free PMC article.
As the underlying pathophysiology of progressive forms of multiple sclerosis (MS) remains unclear, current treatment strategies are inadequate. ...Our study supports the combination of indapamide and HCQ as a new treatment strategy targeting multiple facets o …
As the underlying pathophysiology of progressive forms of multiple sclerosis (MS) remains unclear, current treatment strategie …
Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model.
Safaei HA, Eftekhari SM, Aliomrani M. Safaei HA, et al. Metab Brain Dis. 2021 Oct;36(7):2101-2110. doi: 10.1007/s11011-021-00802-8. Epub 2021 Aug 3. Metab Brain Dis. 2021. PMID: 34342813
It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, and differentiate. This study aimed to investigate the effects of Hydroxychloroquine (HCQ) on the expression of OLIG-2 and PDGFR-alp …
It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, …
Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
Faissner S, Mahjoub Y, Mishra M, Haupeltshofer S, Hahn JN, Gold R, Koch M, Metz LM, Ben-Hur T, Yong VW. Faissner S, et al. Mult Scler. 2018 Oct;24(12):1543-1556. doi: 10.1177/1352458517728811. Epub 2017 Aug 31. Mult Scler. 2018. PMID: 28857721
BACKGROUND: Most multiple sclerosis (MS) patients succumb to a progressive phenotype. ...Minocycline and hydroxychloroquine combined are candidate treatments for progressive MS....
BACKGROUND: Most multiple sclerosis (MS) patients succumb to a progressive phenotype. ...Minocycline and hydroxychloroquine …
Hydroxychloroquine effects on miR-155-3p and miR-219 expression changes in animal model of multiple sclerosis.
Mazloumfard F, Mirian M, Eftekhari SM, Aliomrani M. Mazloumfard F, et al. Metab Brain Dis. 2020 Dec;35(8):1299-1307. doi: 10.1007/s11011-020-00609-z. Epub 2020 Aug 29. Metab Brain Dis. 2020. PMID: 32860610
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system which causes chronic demyelination. Hydroxychloroquine (HCQ) possess immunosuppressive and anti-inflammatory properties. ...
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system which causes chronic demyelination. …
Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
Camara-Lemarroy C, Silva C, Gohill J, Yong VW, Koch M. Camara-Lemarroy C, et al. Eur J Neurol. 2023 Jan;30(1):187-194. doi: 10.1111/ene.15588. Epub 2022 Oct 25. Eur J Neurol. 2023. PMID: 36214614
BACKGROUND: In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are e …
BACKGROUND: In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate of disability worsening at 18 months in p …
Retinal Findings on OCT in Systemic Conditions.
Chhablani PP, Ambiya V, Nair AG, Bondalapati S, Chhablani J. Chhablani PP, et al. Semin Ophthalmol. 2018;33(4):525-546. doi: 10.1080/08820538.2017.1332233. Epub 2017 Jun 22. Semin Ophthalmol. 2018. PMID: 28640657 Review.
English articles up to April 2015 were included. Terms used for search included: Alzheimer's Disease; Multiple Sclerosis; Parkinson's Disease; Behcet's Disease; Schizophrenia; Migraine; Obstructive Sleep Apnea Syndrome; Neurofibromatosis; Sickle Cell Disease; Renal …
English articles up to April 2015 were included. Terms used for search included: Alzheimer's Disease; Multiple Sclerosis; Park …
Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review.
Chakravarty SD, Harris ME, Schreiner AM, Crow MK. Chakravarty SD, et al. Semin Arthritis Rheum. 2012 Oct;42(2):206-12. doi: 10.1016/j.semarthrit.2012.03.008. Epub 2012 May 8. Semin Arthritis Rheum. 2012. PMID: 22572392 Review.
OBJECTIVES: To report a rare case of sarcoidosis induced by chronic interferon-beta (a type I interferon) therapy of multiple sclerosis and to review previously reported cases. METHODS: We describe a patient with a prior diagnosis of multiple sclerosis …
OBJECTIVES: To report a rare case of sarcoidosis induced by chronic interferon-beta (a type I interferon) therapy of multiple scle …
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Plantone D, Koudriavtseva T. Plantone D, et al. Clin Drug Investig. 2018 Aug;38(8):653-671. doi: 10.1007/s40261-018-0656-y. Clin Drug Investig. 2018. PMID: 29737455 Review.
These effects make these drugs a possible option in the treatment of several tumors in association with radiotherapy and chemotherapy. Finally, the repurposing of chloroquine and hydroxychloroquine is currently being examined for neurological diseases such as neurosarcoido …
These effects make these drugs a possible option in the treatment of several tumors in association with radiotherapy and chemotherapy. Final …
34 results